trestolone
Small moleculeexperimental
Trestolone, also known as 7α-methyl-19-nortestosterone (MENT), is an experimental androgen/anabolic steroid (AAS) and progestogen medication which has been under development for potential use as a form of hormonal birth control for men and in androgen replacement therapy for low testosterone levels in men but has never been marketed for medical use. It is given as an implant that is placed into fat. As trestolone acetate, an androgen ester and prodrug of trestolone, the medication can also be given by injection into muscle. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2008 (NCT00812630)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Androgen ReceptorAGONIST
AR agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTrestolone ↗
Also known as
- 17-hydroxy-7-methyl-4-estren-3-one
- 7 alpha-methyl-19-nortestosterone
- 7alpha-methyl-19-nortestosterone
- 7alpha-methyl-19-nortestosterone
- 7alpha-methyl-19-nortestosterone
- 7-methyl-19-nortestosterone
- 7α-methyl-19-nortestosterone
- 7α-methyl-19-nortestosterone
- hmeo
- ment steroid
- trestolone
- trestolone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00812630 | Phase 1 | Dec 1, 2008 | Population Council |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Population Council | Academic/Hospital | 1 | 1 | 1 | 2008 |
1 organizations
Page 1 / 1